Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: A randomized phase II study

Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial

(2011) Michael Manns et al.   ANTIVIRAL THERAPY

4 ONCE DAILY ALISPORIVIR (DEB025) PLUS PEGIFNALFA2A/RIBAVIRIN RESULTS IN SUPERIOR SUSTAINED VIROLOGIC RESPONSE (SVR24) IN CHRONIC HEPATITIS C GENOTYPE 1 TREATMENT NAIVE PATIENTS

(2011) R. Flisiak et al.   JOURNAL OF HEPATOLOGY

Hepatitis C virus resistance to protease inhibitors

(2011) Philippe Halfon et al.   JOURNAL OF HEPATOLOGY

The dawn of a new era in HCV therapy

(2011) Sandra Ciesek et al.   Nature Reviews Gastroenterology & Hepatology

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

(2011) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection

(2011) Kenneth E. Sherman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

(2011) Bruce R. Bacon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir for Retreatment of HCV Infection

(2011) Stefan Zeuzem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

(2011) Ira M. Jacobson et al.   NEW ENGLAND JOURNAL OF MEDICINE

In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435

(2010) O. Lenz et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: A phase 1b multiple ascending dose study

(2010) Nicole Forestier et al.   JOURNAL OF HEPATOLOGY

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection

(2010) Michael P. Manns et al.   JOURNAL OF HEPATOLOGY

Telaprevir for Previously Treated Chronic HCV Infection

(2010) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796

(2009) M. F. McCown et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease

(2009) N. J. Liverton et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients

(2009) Henk W. Reesink et al.   GASTROENTEROLOGY

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

(2009) Dongliang Ge et al.   NATURE